Hatchtech receives FDA special protocol agreement of DeOvo™ phase III studies and strengthens patent portfolio

You may also like

18 October 2016

Clinical Genomics Strenghtens it’s Leadership Team with Multiple Key Appointments

13 August 2018

OneVentures invests in regional Queensland company developing treatments for autoimmune diseases

26 March 2015

Hatchtech Pty Ltd to explore strategic alternatives for commercialization of Xeglyze™ lotion in the U.S.

24 March 2014

charmhealth names Gary Lakin as new CEO

07 April 2019

OneVentures reaches first close of Australia’s first venture credit fund

15 January 2020

Pearson acquires interactive learning technology from Smart Sparrow

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor